Connect Biopharma's Innovative Presentations at EAACI 2025
Connect Biopharma Holdings Limited (NASDAQ: CNTB), a pioneering clinical-stage biopharmaceutical company focused on enhancing care for asthma and chronic obstructive pulmonary disease (COPD), is making waves in the medical community. The company recently announced its plans to present two significant oral presentations at the upcoming European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress.
Presentation Details
The EAACI Congress is set to take place from June 13 to June 16, 2025, with sessions occurring both in Glasgow and online. Connect Biopharma will present groundbreaking new research aimed at improving treatment outcomes for individuals suffering from eosinophilic driven, type 2 asthma.
First Presentation: Exacerbation Reduction
The first abstract, titled Reduction in Annualized Exacerbations with Rademikibart in Eosinophilic Driven, Type 2 Asthma, will be presented by Dr. Rekha Chaudhuri. This presentation, listed under Abstract Number 001671, is part of the Clinical Trials on Airways Diseases session and is scheduled for Friday, June 13th, from 3:00 p.m. to 4:30 p.m. BST.
Second Presentation: Lung Function Improvement
The second presentation, Improvement in Lung Function with Rademikibart in Eosinophilic Driven, Type 2 Asthma, shares the same presenter and session details as the first. Its Abstract Number is 001678, and it aims to showcase the positive impact of Rademikibart on lung function in asthma patients during the same session.
Significance of Rademikibart
Rademikibart represents a next-generation solution aimed at addressing acute asthma exacerbations, a significant concern for many patients and healthcare providers alike. The need for effective treatment options is paramount, with roughly 1 million asthma patients and 1.3 million COPD patients in the U.S. experiencing acute exacerbations every year.
In prior clinical trials, Rademikibart has shown promising results with notable reductions in exacerbation rates and rapid improvements in forced expiratory volume in one second (FEV1), with effects observable within as little as 24 hours. These findings underscore the potential benefits of this innovative treatment for those grappling with asthma and COPD.
Company Overview
Connect Biopharma is committed to transforming the landscape of care for patients suffering from asthma and COPD. Based in San Diego, the company is dedicated to advancing therapies that not only address the acute needs of patients but also enhance their overall quality of life.
To learn more about Connect Biopharma and their groundbreaking initiatives, you can visit www.connectbiopharm.com.
Contact Information
Investor Relations Contact:
Alex Lobo
Precision AQ
Alex.lobo@precisionaq.com
(212) 698-8802
Media Contact:
Ignacio Guerrero-Ros, Ph.D., or David Schull
Russo Partners, LLC
Ignacio.guerrero-ros@russopartnersllc.com
(858) 717-2310 or (646) 942-5604
Frequently Asked Questions
What is the significance of the oral presentations by Connect Biopharma?
The presentations will highlight groundbreaking research on Rademikibart's effects on asthma and COPD, showcasing its efficacy in reducing exacerbations.
Who is presenting the findings at the EAACI Congress?
Dr. Rekha Chaudhuri is the presenter for Connect Biopharma's oral presentations.
When are the presentations scheduled?
The presentations are set for June 13, 2025, during the EAACI Congress in Glasgow and online.
What is Rademikibart?
Rademikibart is a next-generation anti-interleukin-4-receptor alpha (IL-4R?) antibody being developed to treat asthma and COPD effectively.
Where can I find more information about Connect Biopharma?
You can explore more about the company and its innovative approaches by visiting www.connectbiopharm.com.
